Development of effective pilot-scale technology for producing N,N-bis-met-histone H 1.3 used for lymphoma treatment
Much attention is presently devoted to the treatment of lymphoma using monoclonal antibodies. Unfortunately, preparations such as Rituximab (MabThera) are not produced in the Russian Federation and must be imported from abroad. It was shown that Hl-type histones with activities similar to that of Ri...
Saved in:
| Published in: | Pharmaceutical chemistry journal Vol. 46; no. 4; p. 234 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Springer
01-07-2012
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Much attention is presently devoted to the treatment of lymphoma using monoclonal antibodies. Unfortunately, preparations such as Rituximab (MabThera) are not produced in the Russian Federation and must be imported from abroad. It was shown that Hl-type histones with activities similar to that of Rituximab can be used for such therapy. We have developed an pilot-scale technology for the production of recombinant N,N-bis-met-histone H1.3. The activity and purity of the obtained preparation were demonstrated in several tests. The produced amount of active pharmaceutical ingredient was sufficient to start clinical trials in Russia. Key words: N,N-bis-met-histone H1.3, lymphoma, chromatography, technology. |
|---|---|
| AbstractList | Much attention is presently devoted to the treatment of lymphoma using monoclonal antibodies. Unfortunately, preparations such as Rituximab (MabThera) are not produced in the Russian Federation and must be imported from abroad. It was shown that Hl-type histones with activities similar to that of Rituximab can be used for such therapy. We have developed an pilot-scale technology for the production of recombinant N,N-bis-met-histone H1.3. The activity and purity of the obtained preparation were demonstrated in several tests. The produced amount of active pharmaceutical ingredient was sufficient to start clinical trials in Russia. Much attention is presently devoted to the treatment of lymphoma using monoclonal antibodies. Unfortunately, preparations such as Rituximab (MabThera) are not produced in the Russian Federation and must be imported from abroad. It was shown that Hl-type histones with activities similar to that of Rituximab can be used for such therapy. We have developed an pilot-scale technology for the production of recombinant N,N-bis-met-histone H1.3. The activity and purity of the obtained preparation were demonstrated in several tests. The produced amount of active pharmaceutical ingredient was sufficient to start clinical trials in Russia. Key words: N,N-bis-met-histone H1.3, lymphoma, chromatography, technology. |
| Audience | Academic |
| Author | Gusarova, V.D Vorobeva, T.V Gusarov, D.A Kosarev, S.A Shibanova, E.D Evteeva, E.A Sokolova, I.V Bairamashvili, D.I |
| Author_xml | – sequence: 1 fullname: Gusarov, D.A – sequence: 2 fullname: Sokolova, I.V – sequence: 3 fullname: Gusarova, V.D – sequence: 4 fullname: Evteeva, E.A – sequence: 5 fullname: Vorobeva, T.V – sequence: 6 fullname: Kosarev, S.A – sequence: 7 fullname: Shibanova, E.D – sequence: 8 fullname: Bairamashvili, D.I |
| BookMark | eNptjztrwzAUhTWk0CTtfxB0rYJkybI8hvSRQEiXDN2CLF_ZKrZlLCWQf1_1MXQodzhw-c45nAWaDX6AGZpTWjLCcvp-ixYhfFDKKOXZHIUnuEDnxx6GiL3FYC2Y6C6AR9f5SILRHeAIph1855srtn7C4-Trs3FDgw-PB1K5QHqIpHUhpjK8xWzF8TlA_Q13135sfa9xnEDHr547dGN1F-D-V5fo-PJ83GzJ_u11t1nvSSMLSUwthMpLKyotqeVKC2Y1y2VRyUrnJitrXvJMF6VRiTSstDVnUAmR5VxVoPgSPfzENmnCyQ3Wx0mb3gVzWvOCi0JyJRO1-odKV0PvTNpjXfr_MXwCBAJnrQ |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2012 Springer |
| Copyright_xml | – notice: COPYRIGHT 2012 Springer |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Chemistry Pharmacy, Therapeutics, & Pharmacology |
| ExternalDocumentID | A373476386 |
| GroupedDBID | --- -53 -58 -5G -BR -EM -~C .86 .VR 06C 06D 0R~ 0VY 123 1N0 29O 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2~H 30V 4.4 406 408 409 40D 40E 53G 5VS 67Z 6NX 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDBF ABDZT ABECU ABFTV ABHLI ABHQN ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABQBU ABSXP ABTEG ABTKH ABTMW ABULA ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACSNA ACZOJ ADHHG ADHIR ADIMF ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFGCZ AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHBYD AHKAY AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BDATZ BGNMA COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP EBD EBLON EBS EIOEI EJD ESBYG ESX FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS HF~ HG6 HMJXF HQYDN HRMNR HVGLF HZ~ IAO IJ- IKXTQ IWAJR IXC IXD IXE IZIGR IZQ I~X I~Z J-C JBSCW JCJTX JZLTJ KDC KOV LAK LLZTM M4Y MA- MK0 N2Q NB0 NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P9N PF0 PT4 PT5 QOK QOR QOS R89 R9I RHV RIG RNS ROL RPX RSV S16 S27 S3B SAP SCM SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW STPWE SZ9 SZN T13 TSG TSK TSV TUC TUS U2A U9L UG4 UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 XU3 YLTOR Z7U Z7V Z7W Z87 Z8O Z8P Z8Q Z91 ZMTXR ZOVNA ~8M ~A9 ~EX ~KM |
| ID | FETCH-LOGICAL-g676-cd44859f4ba60f38a41fa1567b6ba5c29d3932a79c8d44c19fd31eb442538be83 |
| ISSN | 0091-150X |
| IngestDate | Tue Nov 19 20:57:14 EST 2024 Tue Nov 12 23:23:35 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-g676-cd44859f4ba60f38a41fa1567b6ba5c29d3932a79c8d44c19fd31eb442538be83 |
| ParticipantIDs | gale_infotracmisc_A373476386 gale_infotracacademiconefile_A373476386 |
| PublicationCentury | 2000 |
| PublicationDate | 20120701 |
| PublicationDateYYYYMMDD | 2012-07-01 |
| PublicationDate_xml | – month: 07 year: 2012 text: 20120701 day: 01 |
| PublicationDecade | 2010 |
| PublicationTitle | Pharmaceutical chemistry journal |
| PublicationYear | 2012 |
| Publisher | Springer |
| Publisher_xml | – name: Springer |
| SSID | ssj0010032 |
| Score | 1.9065906 |
| Snippet | Much attention is presently devoted to the treatment of lymphoma using monoclonal antibodies. Unfortunately, preparations such as Rituximab (MabThera) are not... |
| SourceID | gale |
| SourceType | Aggregation Database |
| StartPage | 234 |
| SubjectTerms | Cancer Care and treatment Chromatography Cytokinins Development and progression Drug therapy Hematopoietic stem cells Histones Lymphomas |
| Title | Development of effective pilot-scale technology for producing N,N-bis-met-histone H 1.3 used for lymphoma treatment |
| Volume | 46 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6RcIALggKiUNAeUDkkG2Hvxo9jKa7SSxSpUdVbtS9D1VJXsRMp_55Ze-PdgITgwMWKxpNda7_JZGb87SzAR9ujLs6UpjxhJeWCKypyoyhGxiwWKtbMtEcnXKTzq-xrwQvPn_ey_4o0yhBru3P2H9DuB0UBfkbM8Yqo4_WvcA9YQDYQ7Pgalh70cHNXNbRGTMyo6QvqLc3woW37aosG9qX_HLNlTIBNQ9tmxBiFzkbRhI3WNQanVv1uiyZQ_RCepR6GuIvve1VytTtRbhQ-vmX8rGuxqjat05v0dnRR3eJzbdqQ9nxy-YtyK76c9CzlYtMY00kLN4arYESe7bpfwQzddB5RjFSvQjftKpU3YQ2i87muGrrfNvuEpYyj88ySAQxYNB3C47Pz-ZdF_4oJ3VnXSt7N5f6Tg-hi-RyeubSAnHR4voBH5v4Anpzu1u4Ajt2ybsdk6bfM1WNyTBa--_j2JdSBAZCqJL0BkMAAiDcAgoiS3gDIfPwb_GRGEH5i4W-Vd_CTHv5XsDwrlqcz6k7WoN-SNKFKY1I-zUsuRfK5ZJngUSkwkU9lIsVUxblmGNaLNFcZaqooLzWLjOTo31kmTcZew_Ae538DJEpKiUPpqW2qJDSXsY6lTNA_ZVLgLIfwya7qtf0BNSuhhNv1gd-2jceuPUyHcLSnieurgttv_3z7HTz1pnUEw2a1Nu9hUOv1Bwf8T9YHdTQ |
| link.rule.ids | 315,782,786 |
| linkProvider | Springer Nature |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+of+effective+pilot-scale+technology+for+producing+N%2CN-bis-met-histone+H+1.3+used+for+lymphoma+treatment&rft.jtitle=Pharmaceutical+chemistry+journal&rft.au=Gusarov%2C+D.A&rft.au=Sokolova%2C+I.V&rft.au=Gusarova%2C+V.D&rft.au=Evteeva%2C+E.A&rft.date=2012-07-01&rft.pub=Springer&rft.issn=0091-150X&rft.volume=46&rft.issue=4&rft.spage=234&rft.externalDocID=A373476386 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0091-150X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0091-150X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0091-150X&client=summon |